Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: Unreliability of urinary free cortisol estimation

被引:34
作者
Fink, RS [1 ]
Pierre, LN
Daley-Yates, PT
Richards, DH
Gibson, A
Honour, JW
机构
[1] W Middlesex Univ Hosp, Quest Diagnost Inc, Dept Chem Pathol, Isleworth TW7 6AF, Middx, England
[2] GlaxoSmithKline Res & Dev Ltd, Clin Pharmacol, Greenford UB6 0HE, Middx, England
[3] GlaxoSmithKline, Resp Therapeut Grp, Uxbridge UB11 1BT, Middx, England
[4] UCL Hosp, Dept Chem Pathol, London W1T 4JF, England
关键词
D O I
10.1210/jc.2002-020287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Free cortisol in the urine (UFC) is frequently measured in clinical research to assess whether inhaled corticosteroids (ICS) cause suppression of the hypothalamic-pituitary-adrenal axis. Thirteen healthy male subjects received single inhaled doses (of molar equivalence) of fluticasone propionate (FP), triamcinolone acetonide (TAA), budesonide (BUD), and placebo in this single blind, randomized, cross-over study. UFC output was measured using four commercial immunoassays in samples collected in 12-h aliquots over 24 h. The cortisol production rate was assessed from the outputs of cortisol metabolites. UFC showed a 100% increase over placebo levels in the Abbott TDX assay after the administration of BUD. The other assays detected variable suppression (ranging from 29-61% suppression for FP, 30-62% suppression for TAA, and 25% suppression to 100% stimulation for BUD). Suppression was more pronounced in the first 12 h after TAA and in the second 12 h after FP. Similar suppression was found in each 12-h period after BUD. UFC estimation based on immunoassays after ICS may be an unreliable surrogate marker of adrenal suppression. Many of the published studies describing or comparing the safety of different ICS should be reevaluated, and some should be interpreted with caution.
引用
收藏
页码:4541 / 4546
页数:6
相关论文
共 23 条
[1]   A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration [J].
Argenti, D ;
Shah, B ;
Heald, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (07) :695-702
[2]   Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy - 1. General principles [J].
Chrousos, GP ;
Harris, AG .
NEUROIMMUNOMODULATION, 1998, 5 (06) :277-287
[3]   Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy - 2. Review of the literature [J].
Chrousos, GP ;
Harris, AG .
NEUROIMMUNOMODULATION, 1998, 5 (06) :288-308
[4]   Inhaled corticosteroids and the hypothalamic-pituitary-adrenal (HPA) axis: do we understand their interaction? [J].
Dekhuijzen, PNR ;
Honour, JW .
RESPIRATORY MEDICINE, 2000, 94 (07) :627-631
[5]   Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler [J].
Dempsey, OJ ;
Wilson, AM ;
Coutie, WJR ;
Lipworth, BJ .
CHEST, 1999, 116 (04) :935-940
[6]   Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety [J].
Derendorf, H .
RESPIRATORY MEDICINE, 1997, 91 :22-28
[7]  
EDSBACKER S, 1983, DRUG METAB DISPOS, V11, P590
[8]   Steroid profiling [J].
Honour, JW .
ANNALS OF CLINICAL BIOCHEMISTRY, 1997, 34 :32-44
[9]  
Honour JW, 2000, THORAX, V55, P724
[10]   HYPOTHALAMIC-PITUITARY-ADRENAL AXIS [J].
HONOUR, JW .
RESPIRATORY MEDICINE, 1994, 88 :9-15